


2703-630 3



1

7

# Contents

Contributors .....	xiii
--------------------	------

Preface .....	xv
---------------	----

## PART I

### Reviews and Methods of Quantitation

#### CHAPTER 1

*Clinical Studies of Combination Chemotherapy for Cancer* ..... 103

EMIL FREI III

References ..... 107

CHAPTER 4

X. Miscellaneous Combinations .....	207
XI. Resistance Modulators as Adjunct Antimalarial Chemotherapy .....	209
References .....	211

## CHAPTER 6

### *Quantitation of Synergism and Antagonism of*

<i>Two or More Drugs by Computerized Analysis</i> .....	223
---	-----

## JOSEPH H. CHOU

I. Theory and Equations .....	224
II. Computerized Simulation and Automation .....	225

III. Summary .....	305
--------------------	-----

References .....	306
------------------	-----

## CHAPTER 9

<i>Reversal of Multidrug Resistance in Tumor Cells</i> .....	311
--	-----

G. B. JIANG, YANG, I. M. GREENBERGER, AND S. D. HORVITZ

I. Introduction .....	311
-----------------------	-----

II. Review of the Multidrug Resistance Phenotype .....	312
--	-----

III. Reversal of Multidrug Resistance Phenotype .....	315
---	-----

## CHAPTER 12

### *Enhanced Effects of Drugs That Bind Simultaneously to the Same Macromolecular Target*

409

LUCJAN STREKOWSKI and W. DAVID WILSON

I. Introduction .....	409
II. Interactions with Nucleic Acids .....	410
III. Interactions with Protein Targets .....	436
References .....	438

## CHAPTER 13

### *Biochemical Modulation of 5-Fluorouracil by Metabolites and Antimetabolites*

449

ENRICO MINI and JOSEPH R. BERTINO

I. Introduction .....	449
II. Mechanism of Action of FUra .....	451
III. Sequential Methotrexate-FUra .....	452

IV. Synergism Involving Covalent Self-Assembly of Cytotoxic and

Antimicrobial Agents from Less Bioactive Precursors ..... 520

V. Antagonism Involving Covalent Self-Assembly ..... 528

References ..... 534

CHAPTER 15

*Chemotherapeutic Potentiation through Interaction at the Level of DNA* ..... 541

BEVERLY A. TEICHER, TERENCE S. HERMAN, and J. PAUL EDER

$h$



#### IV. Selective Synergism: The Role for Data Analysis Using the

Median-Effect Equation in the Design of Clinical Drug Trials .....	733
--	-----

V. Conclusion .....	734
---------------------	-----

References .....	734
------------------	-----

Index .....	739
-------------	-----